Key points from article :
Dutch medical robotics company Vitestro has revealed an advanced autonomous blood drawing device.
Device combines artificial intelligence (AI) and ultrasound-guided 3D reconstruction with robotic needle insertion.
It allows almost full automation of the pre-analytical phase of the process.
To reduce high blood test error rates, which are mainly caused by manual variability.
Blood collection, known as phlebotomy, is the most common invasive medical procedure.
Vitestro co-founder and CEO Toon Overbeeke said: "- automation like our blood drawing device is inevitable to solve the industry’s biggest problem.”
It can be used by patients aged 16 years and above, as well as those with comorbidities or puncture difficulty.
Clinical trial of the new device for regulatory approval in Europe from 2023.
Vitestro expects to bring it to the European market in 2024.
